Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has expanded its partnership with ER-Kim to include six additional countries for the commercialization of QRX003, a treatment for Netherton Syndrome. This new agreement adds Turkey, Georgia, Azerbaijan, Greece, Cyprus, and Malta to the existing fifteen countries covered in the initial agreement. With this expansion, Quoin now has a total of 60 countries under distribution agreements for QRX003, which aims to be the first approved treatment for this rare genetic disorder lacking current therapies.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive agreement with Neopharm Medical Supplies to commercialize its investigational drug QRX003 in Israel. This marks the sixth distribution partnership for QRX003 since Quoin's NASDAQ debut in October 2021. The agreement aims to address Netherton Syndrome, a rare genetic disorder with no existing treatment. Quoin's CEO, Dr. Michael Myers, emphasized the importance of expanding the distribution network to ensure global access for patients once the product is approved.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive distribution agreement with ER-Kim to commercialize its investigational treatment QRX003 across 15 Central and Eastern European countries. This marks Quoin's fifth distribution partnership since its public debut in October 2021, expanding its access to Netherton Syndrome patients in crucial regions. With this agreement, Quoin now has partnerships in a total of 53 countries, reaffirming its commitment to providing treatment options for this rare genetic disease.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced a new exclusive Distribution Agreement with OrphanDC for QRX003, aimed at treating Netherton Syndrome, in Brazil, Argentina, and Colombia. This marks the fourth distribution partnership since going public in October 2021. Quoin will supply QRX003 to OrphanDC under a revenue-sharing model. The company has previously secured agreements for other regions, including the Middle East and North Africa, and continues discussions with additional distributors. Netherton Syndrome is a rare genetic disorder with no current cure.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced an exclusive Distribution Agreement with Orpharm LLC for the commercialization of QRX003 in Russia and CIS, intended for treating Netherton Syndrome. This agreement marks the third partnership for QRX003 in two months and reflects Quoin's commitment to increasing patient access. QRX003 is crucial as there are currently no approved treatments for this severe genetic disease. Quoin will supply the product to Orpharm upon regulatory approval.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has signed an exclusive License and Distribution Agreement with Genpharm Services for its investigational treatment QRX003, intended for Netherton Syndrome. Genpharm will commercialize QRX003 in the Middle East and North Africa upon receiving regulatory approvals. This agreement marks Quoin's second licensing deal for QRX003 and includes a revenue-sharing arrangement. Quoin is committed to developing therapies for rare diseases, targeting significant unmet medical needs.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has signed an exclusive License and Distribution Agreement with AFT Pharmaceuticals for QRX003, targeting Netherton Syndrome in Australia and New Zealand. Quoin will receive a 20% royalty on net sales post-regulatory approval. This marks QRX003's first licensing agreement, highlighting Quoin's strategy in rare diseases. AFT's commercial presence and focus on dermatology are expected to enhance product promotion. Currently, Netherton Syndrome has no approved treatments, emphasizing the potential impact of QRX003.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has appointed Gordon Dunn as Chief Financial Officer, effective immediately. With over 30 years of experience, Dunn has held CFO roles in both private and publicly traded companies, including Qured and Innocoll AG. Dr. Michael Myers, CEO of Quoin, expressed confidence in Dunn's capabilities, emphasizing his background in investment banking and private equity. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a promising pipeline targeting conditions like Netherton Syndrome and Epidermolysis Bullosa.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced a partnership with Queensland University of Technology for an exclusive option on a bi-functional protein targeting Netherton Syndrome. The agreement entails funding a pre-clinical program, with an option for an exclusive global license upon completion. No upfront fees are required, but royalties will apply upon product approval. CEO Dr. Michael Myers emphasized that this complements their lead asset, QRX003, further solidifying their commitment to developing treatments for rare diseases.
Quoin Pharmaceuticals Completes Merger
On October 28, 2021, Quoin Pharmaceuticals (NASDAQ: QNRX) announced the successful closing of its merger with Cellect Biotechnology. The merger resulted in Quoin's rebranding and its shares will trade under the symbol QNRX starting October 29, 2021. Quoin secured $21.5 million in gross proceeds from a private placement financing led by Altium Capital, supplementing a previous $5 million investment. The company aims to advance its product pipeline addressing rare diseases, while shareholders retained a significant portion of equity in the merged entity.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
